Is There Something Going On Here? And Some Deeper Thoughts The Dow
First thing I'm noticing is the red line seems to be the support on three occasions, with three distinct periods from 2018 where the DOW dropped to the red line and recovered.
2020 Corona crash has had a somewhat perplexing recovery, which to me defies absolutely all and any logic!
It's absurd the DOW has rallied like it has given the economic horror story that's unfolding and mass unemployment, none of it remotely makes any sense.
The absurdity of the recent gains on the questionable unverified results from Gilead shows that unless you're worth at least 8 figures, have wealthy connected family or friends then you shouldn't put your money in the markets at this point.
-----------------
Personal Thoughts & Musings
Is it setting up for another far steeper drop ? The logical brain of mine thinks that nothing lasts forever and infinite unending economic growth is impossible.
In history and in nature, nothing lasts forever!
The question is how long does this go on for ?
I think we are teetering on the edge of the end of the "20th century / American" era and truly the beginning of the 21st century era, much of the way things were will slowly come to an end in another 30-50 years memories of the 20th will be like the think of the 18-19th centuries today.
The defining moment that people will say the 20th century truly died is when Queen Elizabeth II passes in the near future.
2019
XSPA ready (Golden Cross)XSPA began it's pilot covid-19 testing program this week in contract and in conjunction with JFK airport. More airports to follow and getting lots of media attention. XSPA was featured in a time magazine article today.
I am long with an avg of $4.71.
My price targets for the year are marked. I believe these will be hit by end of year. I will take profit at each target and at any time I may sell my entire position and look for an opportunity to reposition. Trade carefully.
Yea I know I am crazy. GLTA.
Not Financial Advice
Not a recommendation to buy this stock
Novavax (NVAX) stock price is on track...for now [LONG]Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one.
This is purely speculation based on their pipeline. This is not financial advice.
$ROKU PT $115Bring this one down town! I think ROKU can see a nice drop coming down to the $115-$110 range before stabilizing out. The strength on the 45min chart does not look well, but there's some optimism looking at the 1D chart, but even then it's still in range for the set PT of $115. GLTA and stay safe!
Long biased w/ recent settlement with Apotex and tight range.21-May-20 16:10 ET
AMRN
Amarin announces trial to evaluate effects of VASCEPA on patients with COVID-19 (7.28 -0.18)
Amarin today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group.
The company states, "Based on our current understanding of the biological effects of a COVID-19 infection, including that patients at high risk of cardiovascular disease are at higher risk of mortality and severe effects from a COVID-19 infection, and based on data related to the mechanism of action and effects of VASCEPA in lowering cardiovascular risk in certain high-risk patients, it is believed that VASCEPA could play a beneficial clinical role in helping patients infected by the virus."
14-May-20 14:52 ET
AMRN
Amarin announces VASCEPA data from prespecified and post hoc analyses of REDUCE-IT study (7.64 +0.22)
Amarin today announced that data from the REDUCE-IT study presented at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions,showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001). Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001).
The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors.
Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively.
In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005).
Has the flattened curve in US COVID deaths turned into a plateauWeek beginning June 15th, all that' s left is an unfortunate 1500 US Deaths from COVID19 before the 'flattened curve' potentially becomes a plateau. COVID-19 DEATHS_UK showed a similar but earlier pattern but it would be an anomaly in reporting, perhaps, if the chart wasn't pulled from TradingView.
Z1P : 20% BREAK INCOMING! ZIP CO LIMITED (ASX:Z1P) has bounced back significantly well after the market dump in FEB/MAR, as have all lending services due to the job losses/ government surpluses around the world.
When the market reopens on monday I can see a couple of things happening.
1: WE crack this 'strong equilibrium' as price action continues up the trendline and get squeezed into the corner, 20% TARGET
- Respecting Uptrend
- Buyer Volume Present
-Covid19 crisis still taking a toll on the economy (People still borrowing)
If we do break the equilibrium my next target would be the 4.14 Equilibrium. Careful though as 'Bearish Divergence' could follow.
2: The Resistance holds and we break trend, returning to 'Previous Support' 10% TARGET
-Uptrend Trendline Breaks
-Double Top Confirms
-MACD crosses
-.236 Fib Breaks
3: Previous Support Fails and we fall to 2.84 Support. 15% TARGET
-Breaks .236 & .382 Fibs
-Healthy Retrace after 230% move
-MACD will have crossed
-Center BB will have failed
NOTE: There is an OPEN GAP sitting inside the 'Golden Pocket'. Do not be surprised if we see this fill.
Offering simple interest free and flexible repayment options, Strong Retail Affiliations and having an App in the Top 10 of Google Play and Apple, it's easy to see why Z1P is doing so well. They are up $45Million in revenue and have nearly cracked 2 Million Users.
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
COVID-19 France confirmed/recovered/deathsI would like to know someone who studied normalized Gaussian curves with expected value u and variance o2.
In theory, the more we will test people, the more the curve will spike rapidly, to go down rapidly, but it's just mathematics, not epidemiology.
According to epidemiologists, there won't be second wave before September 2020.
Here is the official numbers according to the Regional Health Agency : dashboard.covid19.data.gouv.fr
160 750 confirmed cases
Reduction in confirmed cases due to a change in calculation method.
Since June 2, patients who test positive are only counted once.
29 663
deaths
9 693
hospitalizations
74 612
returns to home
701
in reanimation
19 206
deaths at hospital
37 901
confirmed cases in retirement house and medical social establishment
10 457
deaths in retirement house and medical social establishment
The COVID death curve in India hasn't flattened - false dawn :(Unfortunately, the same thing possibly happening in the USA (COVID-19 DEATHS US) has already happened in India: there was a flattening of the curve but as of week beginning 15th June 2020 the percentage change of deaths is 36.74% matching what it was in week beginning 11th May 2020, 36.75%, and so dispelling any notion of a flattened curve.
TA meets speculative fundamental analysis on SPYSince the "V-shaped" recovery started, we've seen nothing but divergence.
It's mostly speculation, but me and many other people believe this volatile bull run since the start of the COVID-19 crisis is almost solely because of the FED blindly pumping money into securities. While that money is not running out anytime soon, we're seeing a significant volume and momentum slowdown in the last two to three weeks. RSI is the only thing that is not diverging even though the average SRSI is lower recently (the last 2-3 weeks).
More speculation: Multiple news sources are reporting investors becoming more cautious of a "second wave" or "second peak" of the corona virus. I personally believe it's virtually inevitable in the US at least. Here's why:
1) Protests for civil rights have caused thousands of people to gather closely for extended periods of time across weeks (shouting chants and contacting each other directly). Even with masks and other PPE, this presents a great risk of virus propagation.
2) Most states have reopened/partially reopened increasing the amount of contact to the public workers and patrons have. Even with SOME states implementing strict restrictions on the reopening, this presents a great risk of virus propagation, not to mention it has already caused an uptick in the daily new cases within the US.
3) Developing and 3rd world countries are seeing their own first peak in cases. This is driving the record daily new cases across the world we saw yesterday of 146,111 new cases. The record before that was the 6/16 with 143,566 new cases. The record before that was 6/12 with 143,421. (Data provided from worldometers.com) As TA would say, new higher highs with an exponentially increasing moving average would say greater numbers are to come.
So while this bull run could continue for a relatively short period of time (2-3 more weeks), all signs point to a significant pull back that the FED will not be able to revert without significant fiscal policy.
This analysis along with the inverted yield curve, dramatic reduction in consumer spending, dramatic increase in unemployment, and much more, cause me to be conservatively switching back to a bear market strategy across my portfolio.
Heat Biologics HTBX is working on the Covid-19 vaccineHeat Biologics HTBX is one of the lowest market cap companies (65.51M) working on the Covid-19 vaccine. It has a lot of room to grow from it`s peak in Oct 4th 2013 (139,90 usd)
The indiccators are also showing a strong buying power.
Heat Biologics Inc. HTBX has previously announced that it is developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines.
The company also recently joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine, according to Maxim Group analysts.
History Repeats Itself: Those Who Do Not Learn History Are Doomed To Repeat It.
Second wave of virus coming even though Fauci says is still wave 1.
Everything is setup for another bear market, and when Robinhooders start to loose money for their bull positions, they with turn sides and give strenght to bear market like a Domino Effect.
Vix touched bottom on 24.50 and S&P500 futures touched their peak on 3230.
Is a bubble inside another bubble.
Buying stocks of collapsed companies, is no good idea... bubbles DO break!
Fear has been evident for the last 1 and a half week.
ANZ entry sub 18Tested 0.618 Fib and top resistance of downward wedge.
All other major banks NAB. CBA and WBC to follow.
RSI is still relatively high.
1st entry at 18 and will average down to 17 if it falls further.
First entry at the start of an uptrend which most likely gets back tested.
RSI<40
ANZ will most likely hold 17.65 level(GFC bottom)